Cure8 research brief
Patients and clinicians considering long-term use of mirikizumab for Crohn's disease may find evidence here that quality of life and common symptoms (fatigue, abdominal pain, stool frequency) can remain improved out to two years in many participants.
Adults with Crohn's disease, patients on or considering biologic/IL-23 therapy, clinicians treating IBD, and researchers studying long-term biologic outcomes.
This is an extension analysis of patients who came from the VIVID-1 trial and received mirikizumab 300 mg subcutaneously. The study assessed validated patient-reported measures (IBDQ, EQ-5D-5L VAS, WPAI:CD, FACIT-Fatigue) at Weeks 64 and 104 and used standard imputation methods for missing data.
Results reported in the abstract show that a large proportion of prior endoscopic responders and non-responders achieved IBDQ response or remission and meaningful improvements in fatigue and work productivity at two years.
About three quarters of prior endoscopic responders and roughly half of non-responders met the study's PRO-defined clinical remission at Week 104. How to read this These are results from an open-label extension rather than a randomized placebo-controlled comparison, and the abstract-level data do not replace individual medical advice.
The measures reported are patient-reported outcomes rather than objective endoscopic endpoints in this extension analysis.
This summary is grounded in the article abstract (VIVID-2 open-label extension). Open-label extension studies lack randomized control groups and can be influenced by selection and retention biases. The abstract reports patient-reported outcomes; interpretation should consider study design and that full paper review may provide more details.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article reports regulatory approvals and clinical-trial results for Omvoh (mirikizumab), which could offer a new option for people with moderate–severe Crohn’s who still have disruptive symptoms like bowel urgency....
This announces a new FDA‑approved treatment (mirikizumab/Omvoh) for adults with moderately to severely active Crohn disease, offering another option for people who haven’t responded to prior therapies. The approval was...
Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing...
